Patents Assigned to Oncotech, Inc.
-
Publication number: 20090280508Abstract: This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for identifying and characterizing anticancer compounds.Type: ApplicationFiled: December 5, 2006Publication date: November 12, 2009Applicant: ONCOTECH, INC.Inventors: Eugene Mechetner, John Fruehauf
-
Publication number: 20080280768Abstract: The invention provides methods for prognosis, diagnosis, staging and determining disease progression in human cancer patients related to amplification levels of one or a plurality of genetic loci that are differentially amplified in chemotherapeutic drug resistant tumor cells.Type: ApplicationFiled: January 30, 2008Publication date: November 13, 2008Applicant: Oncotech, Inc.Inventors: William A. Ricketts, David L. Smith, Snjezana Covic
-
Patent number: 7323300Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in chemotherapeutic drug resistant and drug sensitive tumor cells.Type: GrantFiled: November 15, 2002Date of Patent: January 29, 2008Assignee: Oncotech, Inc.Inventors: John P. Fruehauf, Eugene Mechetner
-
Patent number: 7282346Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a variety of immunohistochemical and genetic markers associated with poor cancer prognosis, and in particular those markers related to tumor invasiveness, metastasis and spread. The invention also provides methods using a predictive index for prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease. The methods of the invention are useful for making clinical decisions on cancer treatment, surveillance and surgical intervention.Type: GrantFiled: October 16, 2001Date of Patent: October 16, 2007Assignee: Oncotech, Inc.Inventor: John Fruehauf
-
Patent number: 7144704Abstract: This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for identifying and characterizing anticancer compounds.Type: GrantFiled: April 2, 2002Date of Patent: December 5, 2006Assignee: Oncotech, Inc.Inventors: Eugene Mechetner, John Fruehauf
-
Publication number: 20060160114Abstract: The invention provides methods for prognosis, diagnosis, staging and determining disease progression in human cancer patients related to expression levels of one or a plurality of genes or genetic loci that are differentially deleted, amplified, expressed or amplified and over-expressed in chemotherapeutic drug resistant tumor cells.Type: ApplicationFiled: December 2, 2005Publication date: July 20, 2006Applicant: Oncotech, Inc.Inventors: Christopher Kerfoot, William Ricketts, David Smith
-
Patent number: 6998234Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in anti-angiogenic agent-sensitive and anti-angiogenic agent-resistant vascular endothelial cells as compared to baseline vascular endothelial cells.Type: GrantFiled: May 10, 2002Date of Patent: February 14, 2006Assignee: Oncotech, Inc.Inventors: John P. Fruehauf, Eugene Mechetner
-
Publication number: 20040214203Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in chemotherapeutic drug resistant and drug sensitive tumor cells.Type: ApplicationFiled: December 12, 2003Publication date: October 28, 2004Applicant: Oncotech, Inc.Inventor: John P. Fruehauf
-
Publication number: 20030096261Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in anti-angiogenic agent-sensitive and anti-angiogenic agent-resistant vascular endothelial cells as compared to baseline vascular endothelial cells.Type: ApplicationFiled: May 10, 2002Publication date: May 22, 2003Applicant: Oncotech Inc.Inventors: John P. Fruehauf, Eugene Mechemer
-
Publication number: 20030096290Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in chemotherapeutic drug resistant and drug sensitive tumor cells.Type: ApplicationFiled: November 15, 2002Publication date: May 22, 2003Applicant: Oncotech, Inc.Inventors: John P. Fruehauf, Eugene Mechetner
-
Patent number: 6511806Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in chemotherapeutic drug resistant and drug sensitive tumor cells.Type: GrantFiled: November 3, 2000Date of Patent: January 28, 2003Assignee: Oncotech, Inc.Inventors: John Fruehauf, Eugene Mechetner
-
Publication number: 20020039754Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a variety of immunohistochemical and genetic markers associated with poor cancer prognosis, and in particular those markers related to tumor invasiveness, metastasis and spread. The invention also provides methods using a predictive index for prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease. The methods of the invention are useful for making clinical decisions on cancer treatment, surveillance and surgical intervention.Type: ApplicationFiled: October 16, 2001Publication date: April 4, 2002Applicant: Oncotech, Inc.Inventor: John Fruehauf
-
Patent number: 6303324Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a variety of immunohistochemical and genetic markers associated with poor cancer prognosis, and in particular those markers related to tumor invasiveness, metastasis and spread. The invention also provides methods using a predictive index for prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease. The methods of the invention are useful for making clinical decisions on cancer treatment, surveillance and surgical intervention.Type: GrantFiled: November 24, 1998Date of Patent: October 16, 2001Assignee: Oncotech, Inc.Inventor: John Fruehauf
-
Patent number: 6261795Abstract: The present invention provides a novel method for assaying radiation resistance of cancer cells by isolating cancer cells, irradiating the cells, incubating the cells with a labeled marker indicative of cell proliferation, measuring the amount of labeled marker incorporated into the cells in order to determine the effect of radiation on the proliferation of cells, and then determining the relative resistance of the cells to radiation. Also provided are methods of assaying radiation resistance of cancer cells which are exposed to radiation and radio-sensitizing or chemotherapeutic agents.Type: GrantFiled: May 17, 1999Date of Patent: July 17, 2001Assignee: Oncotech, Inc.Inventors: John P. Fruehauf, Ricardo J. Parker
-
Patent number: 6008007Abstract: The present invention provides a novel method for assaying radiation resistance of cancer cells by isolating cancer cells, irradiating the cells, incubating the cells with a labeled marker indicative of cell proliferation, measuring the amount of labeled marker incorporated into the cells in order to determine the effect of radiation on the proliferation of cells, and then determining the relative resistance of the cells to radiation. Also provided are methods of assaying radiation resistance of cancer cells which are exposed to radiation and radio-sensitzing or chemotherapeutic agents.Type: GrantFiled: January 31, 1997Date of Patent: December 28, 1999Assignee: Oncotech, Inc.Inventors: John P. Fruehauf, Ricardo J. Parker
-
Patent number: 5840507Abstract: The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a variety of immunohistochemical and genetic markers associated with poor cancer prognosis, and in particular those markers related to tumor invasiveness, metastasis and spread. The invention also provides methods using a predictive index for prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease. The methods of the invention are useful for making clinical decisions on cancer treatment, surveillance and surgical intervention.Type: GrantFiled: April 11, 1997Date of Patent: November 24, 1998Assignee: Oncotech, Inc.Inventor: John Fruehauf
-
Patent number: 5149527Abstract: Immunopotentiating compositions which are useful in causing tumor necrosis and/or regression in subjects who have previously received successful therapy which destroys tumors and stimulates cytotoxic macrophages are described. The immunopotentiators are administered at a time when formation of macrophages specifically cytotoxic for the tumor have been generated by previous therapy.Type: GrantFiled: September 18, 1990Date of Patent: September 22, 1992Assignee: Oncotech, Inc.Inventor: Larry M. Weisenthal
-
Patent number: 4735895Abstract: The present invention relates to an improved viral transformation/neodifferentiation assay for determining predisposition to cancer. The invention is based on the association between retroviral transformation/neodifferentiation and a predisposition to cancer. The level of lipogenic enzymes is measured in cultured human fibroblast cells after transformation/neodifferentiation with Kirsten murine sarcoma virus in the presence of glucocorticosteroids to monitor the extent of conversion of the human skin fibroblasts to fully mature adipocytes.Type: GrantFiled: December 28, 1984Date of Patent: April 5, 1988Assignee: Oncotech, Inc.Inventor: Levy Kopelovich